Health Topic


A commitment to effective HCV and HBV diagnosis and monitoring since 1993

Hepatitis B and C are among the most common viral infections in the world. About 325 million worldwide in 2015 were carriers of hepatitis B or C virus infections, which can remain asymptomatic for decades.1,2

Every day, approximately 4,000 people die from the consequences of viral hepatitis – 1.4 million people every year.3 Furthermore, each year, 1.75 million people newly acquire hepatitis C virus infection. The disease caused 1.34 million deaths in 2015, a number comparable to annual deaths caused by tuberculosis and higher than those caused by HIV.2

Roche is committed to fighting viral hepatitis, offering a complete continuum of care for the diagnosis and treatment of HCV and HBV. This starts with a focus on  serology based testing for screening and diagnosis followed by PCR testing for confirmation and genotyping (only HCV) and viral load monitoring to determine patient response to treatment.

90% reduction in new cases of chronic hepatitis B and C by 2030



  1. World Hepatitis Alliance What is Viral Hepatitis. Updated 2018 Last accessed November 29, 2018 at
  2. World Health Organization. Global Hepatitis Report 2017. Accessed November 28, 2018
  3. World Health Organization. World Hepatitis Day. Last accessed July 2016 at
  4. WHO Combating hepatitis B and C to reach elimination by 2030 Publication date July 2016 Last accessed November 29 2018 at
Found 0 results in